PharmAthene investors sell 113,560 shares, keep 6.3% stake

By Lisa Kerner

Charlotte, N.C., March 17 - A group of PharmAthene, Inc. investors led by Integrated Core Strategies (US) LLC, Riverview Group LLC and Millennium Management LLC sold 112,560 shares of the company's stock between Jan. 23 and March 16 priced from $0.14 to $2.99 each, according to a schedule 13D/A filed on Tuesday with the Securities and Exchange Commission.

The investors beneficially own 1,643,756 shares, or 6.3%, of the Annapolis, Md., biodefense company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.